Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Ambrx turnaround culminates in $2B takeout by J&J

A fall 2022 reset positioned an ADC for prostate cancer as the biotech’s top priority under new leadership

January 8, 2024 9:37 PM UTC

Ambrx’s $2 billion acquisition by J&J completes a 15-month turnaround during which the biotech made its ADC for prostate cancer its top priority, replaced its CEO and rose from penny stock territory with a pair of data readouts.

As the industry settled into the J.P. Morgan Healthcare Conference on Monday, the purchase of Ambrx Biopharma Inc. (NASDAQ:AMAM) by Johnson & Johnson (NYSE:JNJ) for $28 per share became the latest sign of enthusiasm for antibody-drug conjugates, which drove many of 2023’s largest biotech deals...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article